LIVN•benzinga•
LivaNova Announced 12-month, Top-line Data From Its OSPREY Randomized Controlled Trial, Evaluating Outcomes With The Aura6000 System For The Treatment Of Moderate To Severe Obstructive Sleep Apnea
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 7, 2025 by benzinga